FDA Accelerates Biosimilar Approvals to Drive Down High Biologic Drug Costs
The FDA announced new steps to accelerate approvals for biosimilars (generic biologics), aiming to increase competition and lower prescription drug costs. Full analysis of the regulatory changes.